A prospective, open-label, non-comparative study of ambrisentan with anti-fibrotic agent combination therapy in the treatment of diffuse systemic sclerosis

by Annemarie Schorpion, Max Shenin, Robin Neubauer, Chris T. Derk
Published 2018-05-01